122 related articles for article (PubMed ID: 2151230)
1. Fibrinolysis in patients with diabetic nephropathy determined by plasmin-alpha 2 plasmin inhibitor complexes in plasma.
Yagame M; Eguchi K; Suzuki D; Machimura H; Takeda H; Inoue W; Tanaka K; Kaneshige H; Nomoto Y; Sakai H
J Diabet Complications; 1990; 4(4):175-8. PubMed ID: 2151230
[TBL] [Abstract][Full Text] [Related]
2. [Studies on coagulation-fibrinolytic system in diabetic nephropathy--with reference to plasma TAT and alpha 2PIC].
Watanabe S; Ogihara T; Iyori S; Kaneshige H; Nomoto Y; Sakai H
Nihon Jinzo Gakkai Shi; 1990 Sep; 32(9):995-9. PubMed ID: 2148199
[TBL] [Abstract][Full Text] [Related]
3. Change of lipoprotein (a) and coagulative or fibrinolytic parameters in diabetic patients with nephropathy.
Nagai T
J Atheroscler Thromb; 1994; 1(1):37-40. PubMed ID: 9222867
[TBL] [Abstract][Full Text] [Related]
4. Change of lipoprotein(a) and coagulative or fibrinolytic parameters in diabetic patients with nephropathy.
Nagai T; Tomizawa T; Mori M
Diabetes Care; 1993 Oct; 16(10):1411-2. PubMed ID: 8269808
[No Abstract] [Full Text] [Related]
5. Plasmin-a2-plasmin inhibitor complex in plasma of patients with thromboembolic diseases.
Wada K; Takahashi H; Tatewaki W; Takizawa S; Shibata A
Thromb Res; 1989 Dec; 56(6):661-5. PubMed ID: 2534445
[TBL] [Abstract][Full Text] [Related]
6. Transient increase of plasma lipoprotein(a) in patients with unstable angina pectoris. Does lipoprotein(a) alter fibrinolysis?
Oshima S; Uchida K; Yasu T; Uno K; Nonogi H; Haze K
Arterioscler Thromb; 1991; 11(6):1772-7. PubMed ID: 1834167
[TBL] [Abstract][Full Text] [Related]
7. [Study on coagulation fibrinolytic systems in predialysis patients with chronic renal failure--comparison between patients with chronic glomerulonephritis and patients with diabetic nephropathy].
Nagake Y; Makino H; Yorioka N; Nomura S; Osawa G; Yamakido M; Kawasaki H; Kato Y; Matsuzaki M; Shikata K; Uemasu J; Somiya H; Fujii Z; Hayashida S; Nasu T; Oyabu Y; Nitta Y; Kawanishi H; Usui K; Fujiwara K; Takasugi N; Kanehara K; Hamaguchi N; Kumagai I; Ota Z
Nihon Jinzo Gakkai Shi; 1997 Jul; 39(5):474-82. PubMed ID: 9283213
[TBL] [Abstract][Full Text] [Related]
8. Increased fibrin/fibrinogen degradation products without increase of plasmin-alpha 2-plasmin inhibitor complex after hepatectomy for hepatocellular carcinoma.
Takeda S; Katoh H; Takaki A; Okamoto K; Ohsato K
Thromb Res; 1990 Jan; 57(2):289-300. PubMed ID: 2156347
[TBL] [Abstract][Full Text] [Related]
9. [Urinary-plasmin alpha 2 plasmin inhibitor complex (PIC) in patients with diabetic nephropathy].
Saigo K; Ryo R; Yamaguchi N
Rinsho Byori; 1993 Jul; 41(7):785-8. PubMed ID: 8361049
[TBL] [Abstract][Full Text] [Related]
10. Activation of blood coagulation and fibrinolysis in diabetes mellitus: evaluation by plasma levels of thrombin-antithrombin III complex and plasmin-alpha 2-plasmin inhibitor complex.
Takahashi H; Tsuda A; Tatewaki W; Wada K; Niwano H; Shibata A
Thromb Res; 1989 Sep; 55(6):727-35. PubMed ID: 2528845
[TBL] [Abstract][Full Text] [Related]
11. Coagulation and inflammation in overt diabetic nephropathy: association with hyperhomocysteinemia.
Aso Y; Yoshida N; Okumura K; Wakabayashi S; Matsutomo R; Takebayashi K; Inukai T
Clin Chim Acta; 2004 Oct; 348(1-2):139-45. PubMed ID: 15369747
[TBL] [Abstract][Full Text] [Related]
12. A possible role of thrombin-activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients.
Hryszko T; Malyszko J; Malyszko JS; Brzosko S; Pawlak K; Mysliwiec M
Nephrol Dial Transplant; 2001 Aug; 16(8):1692-6. PubMed ID: 11477176
[TBL] [Abstract][Full Text] [Related]
13. An enzyme-linked immunosorbent assay (ELISA) for the measurement of plasmin-alpha 2-antiplasmin complex in human plasma--application to the detection of in vivo activation of the fibrinolytic system.
Holvoet P; de Boer A; Verstreken M; Collen D
Thromb Haemost; 1986 Oct; 56(2):124-7. PubMed ID: 2433784
[TBL] [Abstract][Full Text] [Related]
14. [Molecular markers of hemostatic-mechanisms--plasmin-alpha 2 plasmin inhibitor complex].
Kawai Y; Watanabe K
Rinsho Byori; 1989 Mar; 37(3):248-55. PubMed ID: 2526263
[No Abstract] [Full Text] [Related]
15. Enhanced fibrinolytic activity during the course of hemodialysis.
Nakamura Y; Tomura S; Tachibana K; Chida Y; Marumo F
Clin Nephrol; 1992 Aug; 38(2):90-6. PubMed ID: 1387598
[TBL] [Abstract][Full Text] [Related]
16. Homogeneous immunoassay for alpha 2 plasmin inhibitor (alpha 2PI) and alpha 2PI-plasmin complex. Application of a sandwich liposome immune lysis assay (LILA) technique.
Hosoda K; Yasuda T
J Immunol Methods; 1989 Jul; 121(1):121-8. PubMed ID: 2526837
[TBL] [Abstract][Full Text] [Related]
17. Excessive fibrinolysis in suspected amyloidosis: demonstration of plasmin-alpha 2-plasmin inhibitor complex and von Willebrand factor fragment in plasma.
Takahashi H; Koike T; Yoshida N; Kitahara O; Hanano M; Shibata A; Aoki N
Am J Hematol; 1986 Oct; 23(2):153-66. PubMed ID: 2944378
[TBL] [Abstract][Full Text] [Related]
18. [Concentration of plasmin complexes with alpha-2-macroglobulin and alpha-2-antiplasmin in blood plasma and serum].
Zhabin SG; Zorin NA
Klin Lab Diagn; 1995; (4):43-4. PubMed ID: 7545523
[TBL] [Abstract][Full Text] [Related]
19. Enhanced coagulation-fibrinolysis in patients on regular hemodialysis treatment.
Nakamura Y; Chida Y; Tomura S
Nephron; 1991; 58(2):201-4. PubMed ID: 1830934
[TBL] [Abstract][Full Text] [Related]
20. Activation of blood coagulation and fibrinolysis in vibration syndrome.
Shunto R; Shirakami A; Ohara A; Toibana N; Saito S
Int Arch Occup Environ Health; 1991; 63(4):293-6. PubMed ID: 1720765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
